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Abstract
The concept of targeting G1 cyclin-dependent kinases (CDKs) in breast cancer treatments is supported by the fact
that the genetic ablation of Cdk4 had minimal impacts on normal cell proliferation in majority of cell types, resulting
in near-normal mouse development, whereas such loss of Cdk4 completely abrogated ErbB-2/neu–induced mam-
mary tumorigenesis in mice. In most human breast cancer tissues, another G1-regulatory CDK, CDK2, is also hy-
peractivated by various mechanisms and is believed to be an important therapeutic target. In this report, we
provide genetic evidence that CDK2 is essential for proliferation and oncogenesis of murine mammary epithelial
cells. We observed that 87% of Cdk2-null mice were protected from ErbB-2–induced mammary tumorigenesis.
Mouse embryonic fibroblasts isolated from Cdk2-null mouse showed resistance to various oncogene-induced
transformation. Previously, we have reported that hemizygous loss of Cdc25A, the major activator of CDK2, can
also protect mice from ErbB-2–induced mammary tumorigenesis [Cancer Res (2007) 67(14): 6605–11]. Thus, we
propose that CDC25A-CDK2 pathway is critical for the oncogenic action of ErbB-2 in mammary epithelial cells, in a
manner similar to Cyclin D1/CDK4 pathway.
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Introduction
Ectopic activation of the cell cycle machinery plays a key role in
tumorigenesis, especially during cellular immortalization and trans-
formation [1]. Previous studies have demonstrated that Cdk4 is
required not only for Ras-mediated transformation in mouse em-
bryonic fibroblasts (MEFs) [2] but also for murine mammary tumor-
igenesis induced by an activated neu transgene under the mouse
mammary tumor virus (MMTV) promoter [3,4]. Cyclin D1, the
major regulatory subunit for Cdk4, is also required for MMTV-
neu–induced mammary tumorigenesis [5]. These studies indicate
that ectopic activation of Cyclin D1/Cdk4 is a critical step for HER2/
neu–mediated mammary tumor initiation. Cyclin E/Cdk2 is known
to play a role parallel but overlapping with Cyclin D/Cdk4 in G1/S
progression [6,7]. A majority of human breast cancer tissues display
overexpression of the Cdk2 activating phosphatase Cdc25A and/
or overexpression of Cyclin E [8–11]. Because both Cdc25A and
Cyclin E can activate cell cycle progression without altering the
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activity of Cdk2, the major question so far remained unanswered
whether Cdk2 is essential for oncogene-induced transformation
and tumorigenesis. To understand the role of Cdk2 in cellular trans-
formation, in this report we have tested the transformation potential
of MEFs isolated from Cdk2−/− mice; and to answer the involvement
of Cdk2 in oncogene-induced mammary tumorigenesis, we have
generated Cdk2-null mice overexpressing neu oncogene under
MMTV promoter and determined the tumor latency. Data obtained
from this study indicate that Cdk2 is essential for oncogene-induced
transformation and MMTV-neu–induced mammary tumorigenesis.
Materials and Methods
Mouse Strains
As Cdk2−/− (null) mice was previously reported to be sterile, the
mice strain was maintained as Cdk2+/− and genotyped as previously
reported [12]. All mice were housed in the animal care facility at North-
western University. MMTV-neumice [13] was initially purchased from
Jackson Laboratory (Bar Harbor, ME) and maintained in the animal
facility. Cdk2−/−;MMTV-neu transgenic mice was generated in a two-
step breeding process. In the first step, Cdk2+/− mice was bred with
MMTV-neu mice to generate Cdk2 +/−;MMTV-neu mice. In the
second step, such heterozygous transgenic mice were intercrossed to
generate Cdk2 −/−;MMTV-neu, Cdk2 +/−;MMTV-neu, and Cdk2+/+;
MMTV-neu littermates for comparative studies.
Histologic Analyses
For histochemical analyses of in vivo tumors, mice carrying palpa-
ble tumors were IP injected with 50 μg/ml BrdU, and 2 hours later,
animals were killed. Tumor tissues were then dissected and fixed in
10% buffered formalin. Fixed tissues were paraffin-embedded and
sectioned using standard procedures. Immunohistochemistry was
performed as described previously [14]. Anti-BrdU monoclonal anti-
body was purchased from Pharmingen (San Diego, CA).
Whole-Mount Analysis of Mammary Glands
Inguinal mammary glands were dissected, spread onto a glass slide,
fixed in 10% buffered formalin, hydrated, stained overnight in 0.2%
carmine (Sigma, St. Louis, MO) and 0.5% AlK(SO4)2, dehydrated
in graded solutions of ethanol, and cleared in Histoclear (National
Diagnostics, Atlanta, GA). Tissues were examined and photographed
using a Zeiss Axioscope invertedmicroscope (Oberkochen, Germany).
Cell Cultures
MEFs were isolated from day 12.5 mouse embryos as previously
described, and cultured in Dulbecco modified Eagle medium sup-
plemented with 10% fetal bovine serum, 2 mM L-glutamine, and
100 μg/ml penicillin/streptomycin. Retrovirus transduction with
H-RasV12 plus a dominant negative mutant of p53 (DNp53) or c-Myc
and subsequent soft-agar colony formation assays were performed as
previously described [2].
Statistical Analyses
Tumor-free survival curve was plotted by the Kaplan-Meier method,
the difference between the strains [Cdk2+/+, Cdk2+/− and Cdk2−/−
with neu oncogene] was compared by the log-rank test analysis, and
P values were determined. P < .05 was considered as significant. The
significance did not change when we used the Wilcoxon test instead.
Results
Mammary Glands in Cdk2-Null Mice Show Branching
Defects with Reduced Luminal Epithelial Cell Proliferation
As both male and female Cdk2-null mice were sterile, the lactation
ability as well as histology of the mammary gland of Cdk2-null ani-
mals has never been tested. To check the development of mammary
gland of wild-type, heterozygous, and homozygous Cdk2 mutant
(Cdk2+/+, Cdk2+/−, and Cdk2−/−) mice, the whole-mount staining
was performed on 5-week-old mice from every genotype group.
Examination of the mammary tissues showed a significantly less
branching pattern in Cdk2−/− mice compared with wild-type and het-
erozygous mice (Figure 1A). Examination of hematoxylin and eosin–
stained mammary tissue sections also showed reduced numbers of
luminal structures in the Cdk2−/− mice (Figure 1B). Further analysis
of cell proliferation as evidenced by BrdU incorporation indicated
decreased proliferation of mammary epithelia in Cdk2-null mice
(Figure 1C ). These observations suggest that Cdk2 is essential for
normal mammary epithelial cell proliferation as well as proper post-
natal development of the mammary gland.
Cdk2-Null Mouse Embryonic Fibroblasts Show Significant
Resistance to Oncogene-Induced Transformation
Previous studies demonstrated that MEFs isolated from Cdk2-null
mice do proliferate without major defects compared with wild-type
and heterozygous MEFs [12,15]. To assess the cellular potential to
undergo transformation, Cdk2−/−, Cdk2+/−, and Cdk2+/+ MEFs at
early passages (passage numbers 3 and 4) were retrovirally transduced
with the H-RasV12 + DNp53 or H-RasV12 + c-Myc, followed by a
colony formation assay in soft agar (Figure 2). When we compared
the number of colonies formed, Cdk2−/− MEFs developed signifi-
cantly fewer colonies in soft agar in response to the combinatory ex-
pression of the oncogenes, compared with Cdk2+/+ and Cdk2+/−
MEFs. Cdk2+/− MEFs developed intermediate number of colonies
under these experimental conditions. These observations indicate
that decreased expression of cyclin-dependent kinase 2 (CDK2) cor-
relates with decreased efficiency of cellular transformation, but such
dosage effect does not significantly alter cell cycle kinetics.
Loss of Cdk2 Increases the Mammary Tumor Latency Induced
by MMTV-neu
A previous study described that Cdk4-null mice show significant
resistance to MMTV-neu–induced mammary tumorigenesis [5]. Pre-
vious studies have demonstrated that the absence of Cdk2 did not
affect the normal cell proliferation in majority of tissues as evidenced
by near-normal mouse development [12,15]. However, so far, it has
been unknown whether Cdk2 disruption has any effect on mammary
tumor growth in vivo. Here, we analyzed the latency and growth of
mammary tumors in Cdk2−/−, Cdk2+/−, and Cdk2+/+ mice in the
presence of neu oncogene under the MMTV promoter. As shown
in Figure 3, both Cdk2+/− and Cdk2+/+ mice develop palpable breast
tumors between 25 and 65 weeks with an average tumor latency of
approximately 35 to 45 weeks. In contrast, only 13% of Cdk2−/−
mice developed tumors with a latency of 45 to 65 weeks. Strikingly,
the remaining 87% Cdk2 −/−;MMTV-neu mice did not show any
detectable mammary tumors during a monitoring period until the
age of 16 months. Such differences were significant (P < .001) com-
pared with wild-type or heterozygous Cdk2 mice carrying the neu
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oncogene. These observations suggest that CDK2 is required for the
development of MMTV-neu–induced breast tumors.
Discussion
In this study, we demonstrated the importance of Cdk2 in oncogene-
induced transformation and mammary tumorigenesis. We have shown
here that CDK2 is critical for murine epithelial cell proliferation
during postnatal mammary development. Previously, it was observed
that CDK4 is essential for mammary gland ductal outgrowth and
branching [4] and absence of Cdk4 protects mice from neu-induced
mammary tumorigenesis [3,4]. The current observations thus suggest
that both CDK2 and CDK4 play essential and nonoverlapping roles in
normal mammary gland development and oncogene-induced mam-
mary tumorigenesis. Whereas activating mutations, amplification,
and/or overexpression of CDK4 are observed in human cancers
[16–18], such changes in CDK2 are rarely observed. Therefore, ques-
tions remained whether CDK2 was required for in vivo tumorigenesis.
Recently, it was reported in case of skin carcinogenesis that forced ex-
pression of CDK4 in keratinocytes can induce hyperproliferation
[19,20], but overexpression of CDK2 alone is not sufficient to induce
keratinocyte hyperproliferation [21]. However, interestingly, Cdk2 dis-
ruption in keratin-5 promoter-driven CDK4 transgenic mice reduced
the formation of malignant squamous cell carcinoma (SCC) [22]. It is
likely that the malignant conversion of skin tumors requires both
CDK4 and CDK2 kinase activity. So, at least in case of skin carcino-
genesis model, CDK2 is an essential downstream component for
Figure 1.Mammary glands from 37-day-old Cdk2-null mice showing branching defects with reduced luminal epithelial cell proliferation.
(A) Mammary tissues from mice with indicated genotypes were examined by whole-mount analysis showing branching phenotypes.
Upper panel, low (4×) magnification; lower panel, high (10×) magnification. (B) Mammary tissues from mice with indicated genotypes
showing hematoxylin and eosin staining on paraffin sections. (C) Similar sections were stained with anti-BrdUrd antibody. Mice were
administered with BrdUrd 2 hours before sacrifice. Representative BrdUrd-positive cells are indicated by arrowhead.
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CDK4. The same scenario may apply to mammary tumorigenesis; the
absence of Cdk4 in mice completely protects them from MMTV-neu–
induced mammary tumorigenesis; and the present study shows that
the absence of Cdk2 significantly protected mice from MMTV-neu–
induced mammary tumorigenesis. Although in 13% of mice, tumor-
igenesis was able to bypass the requirement of CDK2 during the long
latency (approximately 45-65 weeks); in most mice (87%), the absence
of Cdk2 was proven beneficial in suppressing MMTV-neu–induced
tumors. This could be an example of incomplete penetrance, either
attributed to mammary gland developmental defects or compensation
by other G1 CDKs, which needs further investigation. Another critical
question remains: why is the loss of CDK2 not compensated by
CDK4, CDK1, or other CDKs? One possibility is that some check-
point pathways could be activated in response to overexpression of on-
cogene (in this case HER2/neu). To overcome checkpoint barriers,
premalignant cells probably require CDK2 as an amplifier through
Figure 3. Loss of Cdk2 prolongs the latency of murine mammary tumorigenesis induced by the MMTV-neu transgene. Kaplan-Meier
tumor-free survival curves show the median time of tumor-free survival was 262 days for Cdk2+/+;MMTV-neu and 241 days for Cdk2+/−;
MMTV-neu mice. Log-rank test analysis showed no significant difference between the two groups (P = .62). Interestingly, in case of
Cdk2−/−;MMTV-neu group, approximately 87% mice remained tumor-free for an observation period of 18 months (P < .001).
Figure 2. Cdk2 level is rate-limiting for oncogene-induced transformation. MEFs from indicated genotypes were transduced either by (A)
H-RasV12 and DNp53 or by (B) H-RasV12 and c-Myc. To determine the transformation potential, soft agar assay was performed as de-
scribed previously [2]. Numbers of transformed colonies were counted on day 16 after plating and presented as means ± SE from three
independent cell preparations of each genotype. (C) Representative microscopic views of soft agar colonies for genotypes indicated
below 16 days after infection with H-RasV12 + DNp53.
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CDC25A activation, which is rate-limiting for neu-induced tumori-
genesis [23] and also a well-defined event critical for checkpoint bypass
[24–26]. The absence of such an amplification loop may account
for inhibited malignant conversion of hyperproliferative premalignant
cells in Cdk2-null mice. At this point, we speculate that checkpoint-
mediated degradation of CDC25A and subsequent inhibition of
CDK2 form an important tumor-suppressive barrier in mammary
tissues with activated neu. This hypothesis is consistent with our pre-
vious observations that transgenic overexpression of CDC25A in
mammary gland can cooperate with neu-induced mammary tumori-
genesis to form malignant tumors [14], whereas hemizygous loss of
Cdc25A protected it from neu-induced tumorigenesis [23]. It would
be interesting to determine whether deregulated overexpression of
CDC25A in Cdk2-null background can overcome the inhibitory bar-
rier of MMTV-neu–induced tumorigenesis. Work is currently under-
way to address these issues.
Mammary gland development may have unique requirement for
G1 cyclins and CDKs, in contrast to transformation and tumorigen-
esis. For example, although knockout mice lacking Cyclin D1 dis-
played no major abnormalities in ductal branching at least until
puberty [3,27], lack of Cdk4 resulted in more profound defects in
prepubertal mammary gland development [4]. As Cdk4-null females
are infertile, Yu et al. [3] demonstrated by mammary gland transplan-
tation that in wild-type recipient mice, Cdk4-null mammary epithe-
lia can undergo apparently normal pregnancy driven lobuloalveolar
development. In the present work, we also found a substantial defect
in ductal branching in prepubertal Cdk2-null mice. Given the steril-
ity of Cdk2-null females similar to Cdk4-null mice, it is possible that
pregnancy-driven mammary gland development can occur normally
in Cdk2-null mammary epithelia under similar experimental con-
ditions. At this stage, it is unclear whether impaired proliferation of
mammary epithelial cells are related to direct requirement for CDK2
in developmental proliferation or any indirect effect of CDK2 dis-
ruption on estrogen synthesis due to the gonadal defect. It is also
possible that estrogen receptor transcriptional activity is altered in
Cdk2-null mice because Cyclin A/CDK2 has been shown to be in-
volved in the control of estrogen receptor activity [28]. Cyclin E is a
critical activator of CDK2 during G1, but to our knowledge, there is
no report of any mammary gland branching defects in Cyclin E–null
virgin female mice. Thus, impaired proliferation of Cdk2-null mam-
mary epithelial cells could be either a direct defect in the cell cycle
machinery or an indirect effect through perturbed estrogen signaling.
This question awaits further investigations.
Previous studies indicated that Cdk2 is dispensable for mitosis in
most tissues in vivo; however, recent studies including the present
work have demonstrated tissue- and stage-specific requirement of
CDK2 in cell proliferation. CDK2 plays an indispensable role in
meiosis [15], of which the loss causes infertility in both male and
female mice. Although CDK2 is not essential for hippocampal neuro-
genesis in adult mice [29], it is critical for neuronal progenitor cell
proliferation in subventricular zone of adult mice brain [30]. Inter-
estingly, such progenitor cells proliferate normally in Cdk2-null mice
during prenatal period. The postnatal requirement for CDK2 in neu-
ronal progenitors is somewhat reminiscent of postnatal requirement
for CDK4 in neuroendocrine tissues such as the pituitary and pan-
creatic islets [31–33]. The complex cell type–specific requirement for
each CDK observed in adult tissue homeostasis suggests that careful
considerations will be needed when CDK inhibitors are chosen for
future cancer therapies. Whereas certain cancer cells are able to con-
tinue proliferation in the presence of CDK2 inhibitors [34], partic-
ular types of cancer cells, perhaps including breast cancers, may be
selectively sensitive to such inhibitors. Recent studies demonstrated
that the effect of CDK4 and CDK2 loss on oncogene-induced trans-
formation of MEFs is more complex than expected [2,35]. Genetic
ablation of Trp53 in mice, which results in complete absence of the
p53 tumor suppressor protein, could override the tumor suppressive
barrier exerted by CDK4 or CDK2 loss in the presence of an onco-
gene, particularly H-RasG12V [35]. However, in the present study as
well as in our previous study [2], overexpression of DNp53, which
inhibits p53 function, did not abolish the transformation-inhibitory
effect of CDK4 or CDK2 loss, leading to the reduction in oncogene-
induced transformation potential. These different outcomes may re-
flect developmental genetic alterations in Trp53-null embryos, as
opposed to the acute inhibition of p53 function by DN-p53. Fur-
thermore, Puyol et al. [36] recently reported that Cdk2 disruption
resulted in only a modest delay in K-RasG12V–induced lung tumor-
igenesis in mice, whereas Cdk4 disruption markedly inhibited tumor-
igenesis. In the study, Cdk6 disruption had essentially no effect.
These data suggest that ablation of a single CDK could cause differ-
ential impacts on tumorigenesis in cell type– and oncogene-specific
manners. Nonetheless, anti-CDK therapies as a highly effective anti-
cancer strategy are currently under intense evaluation. More investi-
gations using genetically engineered mouse models should provide
further insights into the applications and precautions of anti-CDK
therapeutic intervention against cancer patients.
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